drugset

drugset / Trial / NCT07173478

A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

NCT07173478 ↗

Phase 3 Not yet recruiting 156 enrolled Otsuka Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).

Timeline

Start: 2025-10
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Difamilast	Small molecule	1 %	Topical

Indications